Massive study checks if PCV20 vaccine stops pneumonia in At-Risk adults
NCT ID NCT07251465
First seen Jun 25, 2026 · Last updated Aug 26, 2026 · Updated 3 times
Summary
This study looks at health records of over 800,000 adults to see if the PCV20 vaccine reduces pneumonia cases. Researchers will compare pneumonia rates in people who got the vaccine versus those who did not. The goal is to measure how effective PCV20 is in adults aged 18 and older with conditions that raise their risk for pneumococcal disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PCV20 vaccine
- What this could lead to
- If effective, this could confirm that PCV20 helps prevent pneumonia in adults with higher risk, supporting its wider use.
- What could go wrong
- This is an observational study using existing records, not a controlled trial. Results may be affected by unmeasured differences between vaccinated and unvaccinated groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
846,279 people
The number who actually took part.
- Started
-
Jan 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will include a cohort of adults 19-64 years of age with at least one medical or behavioral risk factor associated with an increased risk of pneumococcal disease and a cohort of adults ≥65 years of age. Individuals who meet the eligibility criteria as of 01 July 2022 or who become eligible during the cohort identification period (01 July 2022 through 31 May 2025) will be included in the study. Individuals could contribute to both the 19-64 and ≥65 years of age cohorts if the individual met the inclusion and exclusion criteria for each respective cohort. Follow-up time will be classified by PCV20 exposure status. Within each cohort (19-64, ≥65 years), individuals can contribute one PCV20-unvaccinated time-segment, one PCV20-vaccinated time-segment, or both.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 19-64 years of age cohort 1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022 2. At least 1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps 3. Age 19-64 years of age on the index date with ≥1 medical condition or risk factor identified during the 1-year continuous enrollment period prior to the index date 4. At least one outpatient visit prior to the index date * 65 years cohort 1. Aged ≥19 at some point between July 1, 2022 and May 31, 2025 with 1-year continuous membership prior to July 1, 2022 2. ≥1 year of continuous enrollment as a KPSC member prior to the index date, allowing for 45-day administrative gaps 3. Age ≥65 years on the index date 4. At least one outpatient visit prior to the index date Exclusion Criteria: 19-64 years of age cohort <!-- --> 1. Received PCV20 prior to June 1, 2022, turning age 19 years, or meeting the medical condition or behavioral risk factor inclusion criteria 2. Vaccinated index date is \>30 days after the first PCV20 vaccination date or \>1 dose of PCV20 is received \<30 days prior to the index date 3. Received PCV15 or PCV21 prior to the index date 4. Received PPSV23 ≤2 years prior to the index date 5. Received PCV13 ≤5 years prior to the index date 6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date * 65 years cohort 1. Received PCV20 prior to June 1, 2022 or prior to turning ≥65 years of age 2. Vaccinated index date is \>30 days after the first PCV20 vaccination date or \>1 dose of PCV20 is received \<30 days prior to the index date 3. Received PCV15 or PCV21 prior to the index date 4. Received PPSV23 ≤2 years prior to the index date 5. Received PCV13 ≤5 years prior to the index date 6. Outcome-related diagnosis code in the EHR \<30 days prior to the index date
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Community acquired pneumonia (CAP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a digital assistant and quick tests stop unnecessary antibiotics for kids?
- Ancient remedies put to the test against pneumonia in the elderly
- Nasal swab could curb unnecessary antibiotics in pneumonia
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?